Puma Biotechnology
(NQ:
PBYI
)
2.380
-0.120 (-4.80%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
327,859
Open
2.480
Bid (Size)
2.200 (2)
Ask (Size)
2.400 (6)
Prev. Close
2.500
Today's Range
2.330 - 2.555
52wk Range
2.130 - 7.730
Shares Outstanding
47,509,765
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Today 16:15 EDT
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Performance
YTD
-47.40%
-47.40%
1 Month
-33.70%
-33.70%
3 Month
-37.20%
-37.20%
6 Month
-55.60%
-55.60%
1 Year
-31.81%
-31.81%
More News
Read More
Puma Biotechnology Reports Second Quarter Financial Results
August 01, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Where Puma Biotechnology Stands With Analysts
July 26, 2024
Via
Benzinga
Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock
June 04, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
July 18, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
June 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
June 02, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Join Russell 3000 Index
May 28, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
May 23, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
May 20, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Puma Biotechnology Reports First Quarter Financial Results
May 02, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
April 19, 2024
Via
InvestorPlace
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
April 18, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
March 20, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 27, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
February 22, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.